1
|
Kraus SM, Samuels P, Jermy S, Laing N, Van der Wall M, September U, Ntsekhe M, Chin A, Moosa S, Sliwa K, Ntusi NAB. Clinical and cardiovascular magnetic resonance profile of cardiomyopathy patients from South Africa: Pilot of the IMHOTEP study. Int J Cardiol 2024; 399:131767. [PMID: 38211678 DOI: 10.1016/j.ijcard.2024.131767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 12/20/2023] [Accepted: 01/07/2024] [Indexed: 01/13/2024]
Abstract
BACKGROUND Cardiomyopathy is an important cause of heart failure, however, there is notable lack of data on causes and manifestations of cardiomyopathy in Africa. AIMS The African Cardiomyopathy and Myocarditis Registry Program (IMHOTEP) aims to address the knowledge gap on etiology, treatment, and outcomes of cardiomyopathy in sub-Saharan Africa. METHODS AND RESULTS We conducted a single-center pilot study to delineate the clinical and cardiovascular magnetic resonance (CMR) phenotypes of cardiomyopathy in South African patients. Assessment of the first 99 adult incident cases [mean age 36.8 ± 12.5 years; females 53.5%] enrolled in IMHOTEP showed that dilated cardiomyopathy (n = 77) was commonest, followed by hypertrophic (n = 13), restrictive (n = 5) and arrhythmogenic (n = 4) cardiomyopathies. A broad range of etiologies were encountered with secondary causes identified in 42% of patients. Onset of symptoms in the peripartum period was observed in 47% of women, and peripartum cardiomyopathy was diagnosed in 32.1% of women recruited. In addition to electrocardiography and echocardiography, CMR was performed in 67 cases and contributed diagnostically in a third of cases. Acute inflammation was rarely observed [2%] on CMR, however, late gadolinium enhancement (LGE) was noted in 92% of cases. CONCLUSION We report a diverse spectrum of causes of cardiomyopathy in the South African population, with secondary, potentially treatable, etiologies in a significant proportion of cases. CMR was useful in delineating specific phenotypes and etiologies, influencing clinical care. A higher-than-expected burden of LGE was observed in this young patient cohort - the implications of which are yet to be determined.
Collapse
Affiliation(s)
- S M Kraus
- Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa; Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Cape Universities Body Imaging Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; South African Medical Research Council/University of Cape Town Extramural Unit on Intersection of Noncommunicable Diseases and Infectious Diseases, Cape Town, South Africa.
| | - P Samuels
- Cape Universities Body Imaging Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; South African Medical Research Council/University of Cape Town Extramural Unit on Intersection of Noncommunicable Diseases and Infectious Diseases, Cape Town, South Africa
| | - S Jermy
- Cape Universities Body Imaging Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; South African Medical Research Council/University of Cape Town Extramural Unit on Intersection of Noncommunicable Diseases and Infectious Diseases, Cape Town, South Africa
| | - N Laing
- Division of Human Genetics, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | - M Van der Wall
- Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | - U September
- Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | - M Ntsekhe
- Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | - A Chin
- Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | - S Moosa
- Department of Radiology, University of Cape Town and Groote Schuur Hospital, South Africa
| | - K Sliwa
- Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa; Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - N A B Ntusi
- Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa; Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Cape Universities Body Imaging Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; South African Medical Research Council/University of Cape Town Extramural Unit on Intersection of Noncommunicable Diseases and Infectious Diseases, Cape Town, South Africa.
| |
Collapse
|
2
|
Schaafsma E, Weich H, Scherman J, Ntsekhe M. First 5-year TAVR/TAVI Outcomes from the South African SHARE-TAVI national registry and the influence of malignancy on late outcomes. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
The South African (SA) national prospective multicentre observational SHARE-TAVI registry aims to provide local outcomes data on all TAVIs in State & Private sectors, to support local evidence-based policy evaluations, comparing outcomes to international data & identifying local variations.
Method
All 20 implant centres voluntarily capture all-comers data into the web-based registry. 2266 patients from 1 Sept 2014 to 28 Feb 2022 had pre-TAVI clinical evaluations and 1502 proceeded to TAVI & had procedural data & complications (VARC2 criteria), 30d & annual follow up recorded. The 5-yr cohort of 289 patients have clinical history and profile similar to international data (Table 1).
Results
Procedural success of 93.43% and 1-year mortality of 15.92% in the 5-yr cohort (STS score 8.85%) are similar to reported international data in early TAVI programmes. All-cause mortality at 5-years is 44.3% (in PARTNER 1 – 67.8%, PARTNER 2.0 – 46.0%), and the greatest proportion of non-cardiac mortality (38.5%) occurs in period >1–2yr post-TAVI (lowest proportion 29.4% in >3–4yr period). Outcomes measures in a more recent 2020 patient cohort (n=219, success 98.63% and 1-yr mortality 8.85%, STS risk score 5.51%) have improved compared to the 5-yr cohort.
Patients with “Prior or current malignancy” (POCM) at TAVI evaluation have increased mortality in both the 1-yr outcome (n=637) cohort, 18.7% 1-yr mortality vs 9.3% in those without POCM, and same trend in the 2-year outcome cohort n=443 (28.0% 2-year mortality vs 12.8% without malignancy). Frail patients with POCM in the 2-yr cohort have substantially higher mortality at 2 years, 34.8% than frail patients without POCM 15.9%
At evaluation 66% of patients are NYHA class III+IV, post-TAVI only 5.9% at 30d & 8.8% at 1-year, at 1-year 30% of patients have maintained improvement by 2 or 3 NYHA classes.
Conclusion
5-yr outcomes in SA are comparable to international data, and procedural outcomes have improved further as to be expected with maturation of the programme and technology. The NYHA class distribution at 1-yr shows improvements which should translate into improved quality of life, future studies should include patient self-reported quality of life assessments to verify this benefit. Malignancy, even if prior, may predict poorer outcomes in the longer term, possibly due to reported higher frailty in these patients. Amongst other factors, prior or current malignancy may be considered relevant when assessing patients for futility for TAVI in SA's severely constrained healthcare resource environment.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Educational and Research Grants from SA Heart Association and Medtronic, Edwards Life Sciences
Collapse
Affiliation(s)
- E Schaafsma
- SA Heart Association , Johannesburg , South Africa
| | - H Weich
- University of Stellenbosch, Cardiology , Cape Town , South Africa
| | - J Scherman
- University of Cape Town, Cardiothoracic Surgery , Cape Town , South Africa
| | - M Ntsekhe
- University of Cape Town, Cardiology , Cape Town , South Africa
| |
Collapse
|
3
|
Bell RM, Basalay M, Bøtker HE, Beikoghli Kalkhoran S, Carr RD, Cunningham J, Davidson SM, England TJ, Giesz S, Ghosh AK, Golforoush P, Gourine AV, Hausenloy DJ, Heusch G, Ibanez B, Kleinbongard P, Lecour S, Lukhna K, Ntsekhe M, Ovize M, Salama AD, Vilahur G, Walker JM, Yellon DM. Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop. Basic Res Cardiol 2022; 117:39. [PMID: 35970954 PMCID: PMC9377667 DOI: 10.1007/s00395-022-00947-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Revised: 08/03/2022] [Accepted: 08/03/2022] [Indexed: 01/31/2023]
Abstract
The Hatter Cardiovascular Institute biennial workshop, originally scheduled for April 2020 but postponed for 2 years due to the Covid pandemic, was organised to debate and discuss the future of Remote Ischaemic Conditioning (RIC). This evolved from the large multicentre CONDI-2-ERIC-PPCI outcome study which demonstrated no additional benefit when using RIC in the setting of ST-elevation myocardial infarction (STEMI). The workshop discussed how conditioning has led to a significant and fundamental understanding of the mechanisms preventing cell death following ischaemia and reperfusion, and the key target cyto-protective pathways recruited by protective interventions, such as RIC. However, the obvious need to translate this protection to the clinical setting has not materialised largely due to the disconnect between preclinical and clinical studies. Discussion points included how to adapt preclinical animal studies to mirror the patient presenting with an acute myocardial infarction, as well as how to refine patient selection in clinical studies to account for co-morbidities and ongoing therapy. These latter scenarios can modify cytoprotective signalling and need to be taken into account to allow for a more robust outcome when powered appropriately. The workshop also discussed the potential for RIC in other disease settings including ischaemic stroke, cardio-oncology and COVID-19. The workshop, therefore, put forward specific classifications which could help identify so-called responders vs. non-responders in both the preclinical and clinical settings.
Collapse
Affiliation(s)
- R M Bell
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | - M Basalay
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | - H E Bøtker
- Aarhus University Hospital and Aarhus University, Aarhus, Denmark
| | - S Beikoghli Kalkhoran
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | - R D Carr
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | | | - S M Davidson
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | - T J England
- Stroke, Division of Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, UK
| | - S Giesz
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | - A K Ghosh
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | - P Golforoush
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | - A V Gourine
- Centre for Cardiovascular and Metabolic Neuroscience, Neuroscience, Physiology and Pharmacology, University College London, London, UK
| | - D J Hausenloy
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
- CVMD, Duke-NUS, Singapore, Singapore
- National Heart Research Institute Singapore, National Heart Centre, Singapore, Singapore
- Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taichung City, Taiwan
| | - G Heusch
- Institute for Pathophysiology, West German Heart and Vascular Center, University of Duisburg-Essen, Duisburg, Germany
| | - B Ibanez
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), IIS-Fundación Jiménez Díaz University Hospital & CIBERCV, Madrid, Spain
- CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
- IIS-Fundación Jiménez Díaz Hospital, Madrid, Spain
| | - P Kleinbongard
- Institute for Pathophysiology, West German Heart and Vascular Center, University of Duisburg-Essen, Duisburg, Germany
| | - S Lecour
- University of Cape Town, Cape Town, South Africa
| | - K Lukhna
- University of Cape Town, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Cape Town, South Africa
| | - M Ovize
- INSERM U1060, CarMeN Laboratory, Université de Lyon, Groupement Hospitalier Est, Bâtiment B13, F-69500, Bron, France
| | | | - G Vilahur
- Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, CIBERCV, Barcelona, Spain
| | - J M Walker
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK
| | - D M Yellon
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
| |
Collapse
|
4
|
Mkoko P, Cupido BJ, Hitzeroth J, Chin A, Ntsekhe M. Profile, presentation and outcomes of prosthetic valve endocarditis in a South African tertiary hospital: Insights from the Groote Schuur Hospital Infective Endocarditis Registry. S Afr Med J 2022; 112:13554. [PMID: 35587808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 04/04/2022] [Indexed: 06/15/2023] Open
Abstract
BACKGROUND Prosthetic valve infective endocarditis (PVE) is associated with high morbidity and mortality. The prevalence of PVE in South African retrospective studies ranges between 13% and 17%. OBJECTIVES To define the clinical profile and outcomes of patients with PVE, and compare them with those of native valve endocarditis (NVE) patients. METHODS We performed a prospective observational study of patients presenting or referred to Groote Schuur Hospital, Cape Town, with definite or possible infective endocarditis (IE) based on the 2015 European Society of Cardiology IE diagnostic criteria. Consenting adult patients who met the inclusion criteria were enrolled into the Groote Schuur Hospital Infective Endocarditis Registry, which was approved by the University of Cape Town Human Research Ethics Committee. This study is an analysis of the patients enrolled between 1 January 2017 and 31 December 2019. RESULTS During the study period, a total of 135 patients received a diagnosis of possible or definite IE (PVE n=18, NVE n=117). PVE therefore accounted for 13.3% of the overall IE cohort. PVE patients had a mean (standard deviation) age of 39.1 (14.6) years, and 56.6% were male. PVE occurred within 1 year of valve surgery in 50.0% of cases. Duke's modified diagnostic criteria for definite IE were met in 94.4% of the PVE cohort. Isolated aortic valve PVE was present in 33.3%, and a combination of aortic and mitral valve PVE in 66.6%. Tissue prosthetic valves were affected in 61.1% of cases. Of the PVE cases, 55.6% were healthcare associated. On transthoracic echocardiography, vegetations (61.1%), prosthetic valve regurgitation (44.4%) and abscesses (22.2%) were discovered. Staphylococcus and Streptococcus species accounted for 38.8% and 22.2% of PVE cases, respectively, and 27.8% of cases were blood culture negative. Valve surgery was performed in 38.7% of the PVE patients, and 55.6% of the patients died during the index hospitalisation. Secondary analysis indicated that the PVE patients were sicker than those with NVE, with a higher frequency of septic shock and atrioventricular block (22.2% v. 7%; p=0.02 and 27.8% v. 12%; p=0.04, respectively). In addition, in-hospital mortality was higher in PVE patients than NVE patients (55.6% v. 31.6%; p=0.04). CONCLUSIONS PVE was uncommon, mainly affecting tissue prosthetic valves and prosthetic valves in the aortic position. Patients with PVE were sicker than those with NVE and had high in-hospital mortality.
Collapse
Affiliation(s)
- P Mkoko
- Division of Cardiology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
| | | | | | | | | |
Collapse
|
5
|
Hoevelmann J, Muller E, Azibani F, Kraus S, Cirota J, Briton O, Ntsekhe M, Ntusi NAB, Sliwa K, Viljoen CA. Prognostic value of NT-proBNP for myocardial recovery in peripartum cardiomyopathy (PPCM). Clin Res Cardiol 2021; 110:1259-1269. [PMID: 33555408 PMCID: PMC8318939 DOI: 10.1007/s00392-021-01808-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Accepted: 01/16/2021] [Indexed: 11/25/2022]
Abstract
Introduction Peripartum cardiomyopathy (PPCM) is an important cause of pregnancy-associated heart failure worldwide. Although a significant number of women recover their left ventricular (LV) function within 12 months, some remain with persistently reduced systolic function. Methods Knowledge gaps exist on predictors of myocardial recovery in PPCM. N-terminal pro-brain natriuretic peptide (NT-proBNP) is the only clinically established biomarker with diagnostic value in PPCM. We aimed to establish whether NT-proBNP could serve as a predictor of LV recovery in PPCM, as measured by LV end-diastolic volume (LVEDD) and LV ejection fraction (LVEF). Results This study of 35 women with PPCM (mean age 30.0 ± 5.9 years) had a median NT-proBNP of 834.7 pg/ml (IQR 571.2–1840.5) at baseline. Within the first year of follow-up, 51.4% of the cohort recovered their LV dimensions (LVEDD < 55 mm) and systolic function (LVEF > 50%). Women without LV recovery presented with higher NT-proBNP at baseline. Multivariable regression analyses demonstrated that NT-proBNP of ≥ 900 pg/ml at the time of diagnosis was predictive of failure to recover LVEDD (OR 0.22, 95% CI 0.05–0.95, P = 0.043) or LVEF (OR 0.20 [95% CI 0.04–0.89], p = 0.035) at follow-up. Conclusions We have demonstrated that NT-proBNP has a prognostic value in predicting LV recovery of patients with PPCM. Patients with NT-proBNP of ≥ 900 pg/ml were less likely to show any improvement in LVEF or LVEDD. Our findings have implications for clinical practice as patients with higher NT-proBNP might require more aggressive therapy and more intensive follow-up. Point-of-care NT-proBNP for diagnosis and risk stratification warrants further investigation.
Collapse
Affiliation(s)
- J Hoevelmann
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Saarland University Hospital, Homburg (Saar), Deutschland
| | - E Muller
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - F Azibani
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - S Kraus
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - J Cirota
- Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - O Briton
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - M Ntsekhe
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - N A B Ntusi
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- Cape Universities Body Imaging Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - K Sliwa
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
- Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
| | - C A Viljoen
- Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| |
Collapse
|
6
|
Shuldiner SR, Wong LY, Peterson TE, Wolfson J, Jermy S, Saad H, Lumbamba MAJ, Singh A, Shey M, Meintjes G, Ntusi N, Ntsekhe M, Baker JV. Myocardial Fibrosis Among Antiretroviral Therapy-Treated Persons With Human Immunodeficiency Virus in South Africa. Open Forum Infect Dis 2021; 8:ofaa600. [PMID: 33511232 PMCID: PMC7813208 DOI: 10.1093/ofid/ofaa600] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 12/05/2020] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Heart failure is a prominent cardiovascular disease (CVD) manifestation in sub-Sarahan Africa. Myocardial fibrosis is a central feature of heart failure that we aimed to characterize among persons with human immunodeficiency virus (PWH) in South Africa. METHODS Cardiovascular magnetic resonance (CMR) imaging was performed among PWH with viral suppression and uninfected controls, both free of known CVD. Plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) were measured. Comparisons by human immunodeficiency virus (HIV) status were made using linear and logistic regression, adjusted for age, sex, and hypertension. RESULTS One hundred thirty-four PWH and 95 uninfected persons completed CMR imaging; age was 50 and 49 years, with 63% and 67% female, respectively. Compared with controls, PWH had greater myocardial fibrosis by extracellular volume fraction ([ECV] absolute difference, 1.2%; 95% confidence interval [CI], 0.1-2.3). In subgroup analyses, the effect of HIV status on ECV was more prominent among women. Women (vs controls) were also more likely to have elevated NT-proBNP levels (>125 pg/mL; odds ratio, 2.4; 95% CI, 1.0-6.0). Among all PWH, an elevated NT-proBNP level was associated with higher ECV (3.4% higher; 95% CI, 1.3-5.5). CONCLUSIONS Human immunodeficiency virus disease may contribute to myocardial fibrosis, with an effect more prominent among women. Research is needed to understand heart failure risk among PWH within sub-Saharan Africa.
Collapse
Affiliation(s)
- Scott R Shuldiner
- Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Lye-Yeng Wong
- Department of Surgery, Oregon Health and Science University, Portland, Oregon, USA
| | - Tess E Peterson
- School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| | - Julian Wolfson
- School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| | - S Jermy
- Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - H Saad
- Department of Medicine, University of Cape Town, Cape Town, South Africa
| | | | - A Singh
- Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - M Shey
- Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - G Meintjes
- Department of Medicine, University of Cape Town, Cape Town, South Africa
- Wellcome Centre for Infectious Diseases Research in Africa, Cape Town, South Africa
- Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa
| | - N Ntusi
- Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - M Ntsekhe
- Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - J V Baker
- Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
| |
Collapse
|
7
|
Schaafsma E, Scherman J, Weich H, Ntsekhe M. TAVI In South Africa's resource-constrained economy: the role of local data in overcoming funding resistance. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
The South African (SA) prospective multi-centre observational SHARE-TAVI registry aims to provide local outcomes data on all TAVIs in State & Private sectors, to support local evidence-based policy evaluations, comparing outcomes to international data & identifying local variations.
Methods and results
All 14 implants centres voluntarily capture data into the web-based SHARE-TAVI registry. 1375 patients from Sept 2014-Jan 2020 had pre-TAVI clinical evaluations, 998 proceeded to TAVI & procedural data & complications recorded (VARC-2 criteria), 30d & annual follow up. State sector hospitals provide limited tertiary cardiac care due to severe resource constraints. 13% of TAVIs in SA are in State teaching hospitals, 6.2% of State implants are 2nd generation (2G) devices. In the Private sector the roll-out of TAVI is inhibited by funding resistance, particularly to higher-cost 2G valves. 1st generation (1G) implants comprise 30% of 2019 implants, funding policies leave patients with unaffordable co-payments for 2G valves. Local data (Table 1) shows peri- & 1-year mortality, & procedural success (average 95.4%, & in 2019 98.91%), which are comparable with international data. TAVI in SA is successful despite low volumes & resource limitations. Local data supports superiority of 2G over 1G i.t.o this data and hospital stay length, & unplanned valve-in-valves. No significant differences between 1G & 2G in re-admissions in year 1, but improved quality of life patients experience with TAVI implantation is notable in the NYHA class.
Funding Acknowledgement
Type of funding source: Other. Main funding source(s): SA Heart Association registry project funding. Unrestricted educational grants by Medtronic and Edwards Life Sciences
Collapse
Affiliation(s)
- E Schaafsma
- SA Heart Association, Johannesburg, South Africa
| | - J Scherman
- University of Cape Town, Cardiothoracic Surgery, Cape Town, South Africa
| | - H Weich
- University of Stellenbosch, Cardiology, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Cardiology, Cape Town, South Africa
| |
Collapse
|
8
|
Hoevelmann J, Viljoen C, Azibani F, Imamdim A, Kraus S, Cirota J, Briton O, Ntsekhe M, Ntusi N, Sliwa K. Prognostic value of NT-pro-BNP for myocardial recovery in peripartum cardiomyopathy. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Peripartum cardiomyopathy (PPCM) is an important cause of pregnancy-associated heart failure and occurs in women towards the end of pregnancy or within the first five months post-partum. Though PPCM is mostly associated with left ventricular (LV) recovery, many affected women develop chronic heart failure with persistently reduced LV ejection fraction (LVEF). Despite recent advances in the treatment of PPCM, clinical predictors of myocardial recovery remain sparse.
Purpose
N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is the only clinically established biomarker with diagnostic value in PPCM. However, its prognostic value for LV recovery in PPCM remains uncertain. We aimed to establish whether NT-pro-BNP could serve as a predictor of LV recovery in PPCM, and if so, which levels would help with such risk stratification.
Methods
Women with PPCM seen at the Cardiomyopathy Clinic at Groote Schuur Hospital were recruited between 2012 and 2018. Clinical details and echocardiographic features were recorded at baseline and follow-up, and NT-pro-BNP was measured at baseline. LV recovery was defined as an LVEF of ≥50% at 12-month follow-up.
Results
This cohort of 42 women with PPCM had a mean age of 29.3±5.8 years and median parity of 2 (IQR 1–4). Almost half (45.2%) presented with a NYHA functional class III/IV. The median systolic and diastolic blood pressures were 117mmHg (IQR 105–133) and 75mmHg (IQR 68–85) respectively. The median heart was 94bpm (IQR 74–103). At diagnosis, mean LVEF was 31.1±8.4% and LV end-diastolic dimension (EDD) of 59mm (IQR 53–64), which improved to LVEF 44.5%±14.5 (p=0.001) and LVEDD 53.6mm (p=0.007) at 1 year. Median NT-pro-BNP at presentation was 915.8pg/mL (IQR 613.6–2422.5). Patients presenting with sinus tachycardia (heart rate >100 bpm) had significantly higher NT-pro-BNP values (1815 vs. 728pg/mL, p=0.009) at the time of diagnosis. At presentation, NT-pro-BNP tended to correlate with LVEDD (R 0.33, p=0.04) and was inversely correlated with LVEF (R −0.39, p=0.01). Whereas initial LVEDD and LVEF did not predict LV recovery at 1 year, NT-pro-BNP at the time of diagnosis had prognostic significance. Patients without LV recovery had a significantly higher NT-pro-BNP at diagnosis (1694.1pg/mL vs. 613.1pg/mL, p=0.02). As shown in Figure 1, NT-pro-BNP of >900pg/mL was associated with lower probability of LV recovery (OR 0.19 [95% CI 0.05–0.73], p=0.018).
Conclusion
We show, for the first time, that NT-pro-BNP has a prognostic value for LV recovery in PPCM. NT-pro-BNP may be useful in the risk stratification in PPCM and may be used to recommend more intensive follow-up of patients who have a NT-pro-BNP >900pg/mL at diagnosis.
Figure 1
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): This study was supported by the South African Medical Research Council and National Research Foundation of South Africa.
Collapse
Affiliation(s)
- J Hoevelmann
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - C.A Viljoen
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - F Azibani
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - A Imamdim
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - S Kraus
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - J Cirota
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - O Briton
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - N.A.B Ntusi
- University of Cape Town, Department of Medicine, Cape Town, South Africa
| | - K Sliwa
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| |
Collapse
|
9
|
Hoevelmann J, Viljoen CA, Millar RS, Manning K, Ntsekhe M, Sliwa K. Reply to '12‑lead ECG as an emerging risk stratifier in peripartum cardiomyopathy'. Int J Cardiol 2019; 297:91. [PMID: 31431295 DOI: 10.1016/j.ijcard.2019.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Revised: 07/31/2019] [Accepted: 08/05/2019] [Indexed: 10/26/2022]
Affiliation(s)
- J Hoevelmann
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa; Hannover Medical School, Department of Cardiology and Angiology, Hannover, Germany
| | - C A Viljoen
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa; University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - R S Millar
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - K Manning
- University of Cape Town, Department of Medicine, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - K Sliwa
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa.
| |
Collapse
|
10
|
Kraus SM, Samuels P, Laing N, Ntsekhe M, Chin A, Moosa SM, Sliwa K, Ntusi N. 6133Profile of cardiomyopathy patients in Cape Town - pilot phase the IMHOTEP Study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Cardiomyopathies pose a great challenge because of poor prognosis and high prevalence in LMIC with limited access to specialised care. Little is known about the clinical profile of cardiomyopathy in Africa.
Purpose
Delineation of clinical presentation and cardiovascular magnetic resonance (CMR) phenotypes of cardiomyopathy.
Method
The African Cardiomyopathy and Myocarditis Registry Program (IMHOTEP) is a prospective multi-centre, hospital-based study and aims to investigate the clinical characteristics, aetiology, genetics, management and outcomes of cardiomyopathies in Africans.
Results
Assessment of the first 99 adult cases showed that dilated cardiomyopathy (DCM; n=67) was commonest, followed by hypertrophic (HCM; n=13), left ventricular noncompaction (LVNC; n=11), restrictive (RCM; n=4) and arrhythmogenic (ARVC; n=4) cardiomyopathies. Idiopathic DCM (22%) and peripartum cardiomyopathy (16%) accounted for the majority (Figure). A family history of cardiomyopathy or SCD was reported in 20% of cases. Mean age of presentation was 37±12 years. Most patients (96%) were symptomatic at presentation. NYHA class III/IV was more frequently seen in DCM (61%), RCM (50%) and LVNC (64%), whereas syncope was more common in ARVC (50%) and HCM (23%). VT and aborted cardiac arrest were reported in 7% and 3%, respectively. Onset of symptoms in the peripartum period was observed in 47% of women. Beta-blockers and ACE-inhibitors were prescribed in 77% and 78%, respectively, however optimal dosing was achieved in ≤14% of patients at a median time of 5.4 months after symptom onset. CMR was performed in 67 (68%) cases (Table) and contributed diagnostically in a third of cases. Late gadolinium enhancement (LGE) was observed in 92%. In DCM, linear mid-wall and subendocardial patterns of LGE were seen in 95% and 8% of patients respectively – a much higher percentage than previously reported in the literature.
CMR volumetric and functional assessment DCM, n=38 HCM, n=11 ARVC, n=3 RCM, n=4 LVNC, n=11 LVEF (%) 27±15 78±7 55±5 52±7 32±17 LVEDV/BSA (ml/m2) 150±40 80±17 98±12 59±13 155±52 LV mass/BSA (g/m2) 82±23 102±35 74±3 71±14 88±31 RVEF (%) 34±15 68±10 22±15 49±18 33±15 RVEDV/BSA (ml/m2) 104±37 68±15 189±27 56±8 106±51 All continuous variables presented as mean ± standard deviation.
Cardiomyopathy diagnosis (n=99)
Conclusion
IMHOTEP is the first multi-centre registry for cardiomyopathy in Africa. Preliminary data suggests an earlier age of onset with female predominance compared to other cohorts, and DCM is the predominant form of cardiomyopathy in Africa.
Acknowledgement/Funding
NEWTON FUND NON-COMMUNICABLE DISEASE - South African Medical Research Council (SAMRC/GSK)
Collapse
Affiliation(s)
- S M Kraus
- University of Cape Town, Cape Town, South Africa
| | - P Samuels
- University of Cape Town, Cape Town, South Africa
| | - N Laing
- University of Cape Town, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Cape Town, South Africa
| | - A Chin
- University of Cape Town, Cape Town, South Africa
| | - S M Moosa
- University of Cape Town, Cape Town, South Africa
| | - K Sliwa
- University of Cape Town, Cape Town, South Africa
| | - N Ntusi
- University of Cape Town, Cape Town, South Africa
| |
Collapse
|
11
|
Viljoen CA, Sliwa K, Azibani F, Johnson MR, Baard J, Osman A, Briton O, Ntsekhe M, Anthony J, Chin A. P2533Prospective randomized study on implanted cardiac rhythm recorders in pregnant women with symptomatic arrhythmia and/or structural heart disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Cardiac arrhythmia is an important cause of maternal morbidity and mortality in pregnancy, but is difficult to diagnose.
Purpose
The aim of this single-centre, prospective, randomized pilot study was to compare the implantable loop recorder (ILR) with standard assessment of arrhythmia (12-lead ECG; 24-hour Holter ECG) in terms of acceptability, detection of arrhythmias and impact on outcome in pregnant women with symptomatic arrhythmias and/or structural heart disease (SHD).
Methods
The study recruited 40 consecutive patients from a weekly, dedicated cardiac obstetric clinic. Inclusion criteria: symptoms of arrhythmia and/or having SHD at risk of arrhythmia. Patients were randomized to either standard care (SC) or standard care plus ILR (SC-ILR). ILR recordings were read at the monthly visits and/or when presenting with symptoms.
Results
There were no demographic differences between the study groups. Seventeen patients consented to ILR insertion, all of whom found the procedure acceptable. No arrhythmias were recorded by the 12-lead ECGs. Holter monitoring detected arrhythmias in 10 of 23 patients (43%) from the SC group. In the SC-ILR group, 8 of 17 patients (47%) had arrhythmias detected by Holter, whereas 13 of 17 patients (76%) patients had arrhythmias detected by ILR (p=0.157). One of 4 patients with supraventricular tachycardia, 2 of 3 patients with premature ventricular complexes and 2 patients with paroxysmal atrial fibrillation (AF) recorded by ILR did not have the arrhythmias detected by Holter monitoring (Figure 1A shows a scatter plot of the variable R-R intervals seen in AF and 1B a rhythm strip of AF with irregular RR intervals and the absence of P waves, both downloaded from the ILR). Four of these 5 patients (80%) had a change in management as a direct result of their ILR recordings. There were no maternal deaths up to 42 days postpartum in either of the study groups. Nine babies were born with a low birthweight (<2500g), 5 stillbirth/neonatal deaths and 1 pregnancy termination occurred (5 in the Holter group and 1 in ILR group, p=0.37).
Figure 1
Conclusion(s)
This study suggests that an ILR is an acceptable diagnostic modality in pregnant women with a suspected or at risk of arrhythmia. The ILR increased the diagnostic yield to detect arrhythmias that were not detected by routine ECG and Holter monitoring which led to a change in management in the SC-ILR group and was associated with better maternal and neonatal outcomes. The impact of ILR monitoring should be further assessed in larger studies with longer follow up.
Collapse
Affiliation(s)
- C A Viljoen
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - K Sliwa
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - F Azibani
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - M R Johnson
- Imperial College London, London, United Kingdom
| | - J Baard
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - A Osman
- University of Cape Town, Division of Obstetrics and Gynaecology, Cape Town, South Africa
| | - O Briton
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - J Anthony
- University of Cape Town, Division of Obstetrics and Gynaecology, Cape Town, South Africa
| | - A Chin
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| |
Collapse
|
12
|
Schaafsma E, Weich H, Scherman J, Ntsekhe M. P3692Funding resistance and 1-year outcomes in SHARE-TAVI, a local South African TAVR/TAVI registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Access to tertiary cardiac services is limited in South Africa's (SA) resource-constrained system. SHARE-TAVI, a prospective multi-centre observational registry, aims to capture data for all SA TAVI patients, to compare outcomes to international data & define local variations in clinical presentation & outcomes.
Methods and results
Participation in this voluntary registry, with 93% capture compliance, was incentivized by linking the capture of TAVI evaluation data with the funding application process, leading to a reduction in funding decision waiting time from average +180 days (2014) to current average of 92 days. Restrictive funding policies limit the expansion of TAVI in SA, with approximately 200 TAVIs recorded annually each in 2017 and 2018 from combined participation of 8 Private and 3 State TAVI centres, 9 of which do <20 implants/year.
From Sept 2014 to Dec 2018 inclusive, 894 patients were entered into the registry as part of TAVI evaluations, currently 102 patients await funding decisions (outstanding decisions ranging from 2–1185d). Deteriorating patient health during delayed Funder responses resulted in mortality prior to TAVI date for 8 patients whose funding was approved, & ineligibility for TAVI due to deterioration for 9 awaiting decisions (mean wait 115d). Mortality occurred in 21 others awaiting funding approval. 36% of patients declined funding (n=21/59) died within 1 year.
For the 663 patients who received implants, procedural & complications data were entered according to VARC-2 criteria, & postoperative follow-up at 30d & annually to 5 years. The implanted cohort is comparable to similar registry & trial populations (GARY, SOURCE 3, & US Corevalve Pivotal), in mean age [80.1±7.2yrs], gender [54.9% male], & mean risk predictions 7.0±7.4% [STSPROM], 23.0±15.7 [logEuroSCORE] & 6.4±5.0% [EuroSCORE 2], and Clinical History/Risk.
All-cause mortality of 10.48% (n=48/458) at 1-year compares favourably to published TAVI populations [14,2% US Corevalve, 12.6% SOURCE 3, 20% GARY], with non-cardiac mortality at 33% (n=16/48) mostly attributable to cancer, pneumonia and renal failure. State and Private care offer similar procedural success (State 93.1%, Private 93.7%), and hospital stays - mean ICU [State 1.43±1.58d, Private 2.48±1.99d] & total length of stay [State LOS 4.51±2.87d, Private LOS 5.19±4.24d]. At 30d new permanent pacemaker implantation is needed in 7.5% patients (n=50/663), & in 9.85% at 1-year (n=45/458), these comparatively low rates are being investigated in a sub-study of SHARE-TAVI.
Conclusions
Cumbersome TAVI funding processes & funding resistance contribute to unacceptable mortality figures in appropriately selected patients awaiting funding approval decisions, despite the SHARE-TAVI registry offering independent local data that confirms that TAVI in local resource-constrained settings compares favourably to international best practice standards, even with relatively low volumes at both State and Private centres.
Acknowledgement/Funding
Edwards and Medtronic Unrestricted Educational grants, SA Heart Association Registry Projects
Collapse
Affiliation(s)
- E Schaafsma
- SA Heart Association, Johannesburg, South Africa
| | - H Weich
- University of Stellenbosch, Cardiology, Cape Town, South Africa
| | - J Scherman
- University of Cape Town, Cardiology, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Cardiology, Cape Town, South Africa
| |
Collapse
|
13
|
Hoevelmann J, Viljoen CA, Manning K, Baard J, Hahnle L, Ntsekhe M, Bauersachs J, Sliwa K. The prognostic significance of the 12-lead ECG in peripartum cardiomyopathy. Int J Cardiol 2018; 276:177-184. [PMID: 30497895 DOI: 10.1016/j.ijcard.2018.11.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2018] [Revised: 10/24/2018] [Accepted: 11/05/2018] [Indexed: 01/13/2023]
Abstract
BACKGROUND Peripartum cardiomyopathy (PPCM) is an important cause of pregnancy-associated heart failure, which appears in previously healthy women towards the end of pregnancy or within five months following delivery. Although the ECG is widely used in clinical practice, its prognostic value has not been established in PPCM. METHODS We analysed 12-lead ECGs of patients with PPCM, taken at index presentation and follow-up visits at 6 and 12 months. Poor outcome was determined by the composite endpoint of death, readmission, NYHA functional class III/IV or left ventricular ejection fraction (LVEF) of ≤35% at follow-up. RESULTS This cohort of 66 patients had a median age of 28.59 (IQR 25.43-32.19). The median LVEF at presentation (33%, IQR 25-40) improved significantly at follow-up (LVEF 49%, IQR 38-55, P < 0.001 at 6 months; 52% IQR 38-57, P = 0.001 at 12 months). Poor outcome occurred in 27.91% at 6 months and 41.18% at 1 year. Whereas sinus tachycardia at baseline was an independent predictor of poor outcome at 12 months (OR 6.56, 95% CI 1.17-20.41, P = 0.030), sinus arrhythmia was associated with event free survival (log rank P = 0.013). T wave inversion was associated with an LVEF ≤35% at presentation (P = 0.038), but did not predict poor outcome. A prolonged QTc interval at presentation (found in almost half of the cohort) was an independent predictor of poor outcome at 6 months (OR 6.34, 95% CI 1.06-37.80, P = 0.043). CONCLUSION(S) A prolonged QTc and sinus tachycardia at baseline were independent predictors of poor outcome in PPCM at 6 months and 1 year respectively.
Collapse
Affiliation(s)
- J Hoevelmann
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa; Hannover Medical School, Department of Cardiology and Angiology, Hannover, Germany
| | - C A Viljoen
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa; University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - K Manning
- University of Cape Town, Department of Medicine, Cape Town, South Africa
| | - J Baard
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa
| | - L Hahnle
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa; University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Division of Cardiology, Cape Town, South Africa
| | - J Bauersachs
- Hannover Medical School, Department of Cardiology and Angiology, Hannover, Germany
| | - K Sliwa
- University of Cape Town, Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa.
| |
Collapse
|
14
|
Azibani F, Libhaber E, Baard J, Osman A, Zuhlke L, Lachmann A, Chin A, Ntsekhe M, Soma-Pillay P, Johnson MR, Roos-Hesselink J, Anthony J, Sliwa K. P1563Reducing late maternal death due to cardiovascular disease by targeted interventions. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Azibani
- University of Cape Town, Medicine, Cape Town, South Africa
| | - E Libhaber
- University of the Witwatersrand, Soweto Cardiovascular Research Unit, Johannesburg, South Africa
| | - J Baard
- University of Cape Town, Medicine, Cape Town, South Africa
| | - A Osman
- University of Cape Town, Obstetrics & Gynaecology, Cape Town, South Africa
| | - L Zuhlke
- University of Cape Town, Department of Paediatrics, Cape Town, South Africa
| | - A Lachmann
- University of Cape Town, Obstetrics & Gynaecology, Cape Town, South Africa
| | - A Chin
- University of Cape Town, Cardiology, Cape Town, South Africa
| | - M Ntsekhe
- University of Cape Town, Cardiology, Cape Town, South Africa
| | - P Soma-Pillay
- University of Pretoria, 6 Department of Obstetrics and Gynecology, Maternal and Foetal Medicine, Pretoria, South Africa
| | - M R Johnson
- Imperial College London, London, United Kingdom
| | - J Roos-Hesselink
- Erasmus Medical Center, Department of Cardiology, Rotterdam, Netherlands
| | - J Anthony
- University of Cape Town, Obstetrics & Gynaecology, Cape Town, South Africa
| | - K Sliwa
- University of Cape Town, Medicine, Cape Town, South Africa
| |
Collapse
|
15
|
Weich H, Scherman J, Schaafsma E, Ntsekhe M. P4263Outcomes in a resource-constrained economy: results from the multi-centre South African SHARE-TAVI registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H. Weich
- University of Stellenbosch, Cardiology, Cape Town, South Africa
| | - J. Scherman
- University of Cape Town, Cardiology, Cape Town, South Africa
| | - E. Schaafsma
- University of Cape Town, Cardiology, Cape Town, South Africa
| | - M. Ntsekhe
- University of Cape Town, Cardiology, Cape Town, South Africa
| | | |
Collapse
|
16
|
Wolske J, van Veen K, Syed F, Russell J, Tibazarwa K, Ntsekhe M, Mayosi B, Wilkinson R, Lange C, Wilkinson K. Does tuberculous pericardial disease severity have distinct immunological features? Pneumologie 2009. [DOI: 10.1055/s-0029-1213943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Syed FF, Aje A, Ntsekhe M, Mayosi BM, Moosa S, Tshifularo M, Smedema JP. Resolution of nodular myocardial tuberculosis demonstrated by contrast-enhanced magnetic resonance imaging. Cardiovasc J Afr 2008; 19:198-199. [PMID: 18776963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
In sub-Saharan Africa, pericardial tuberculosis is frequently diagnosed in HIV sero-positive patients. Myocardial involvement has only rarely been reported. We present an HIV sero-positive patient in whom both pericardial and myocardial tuberculosis were diagnosed, and highlight the value of cardiac magnetic resonance imaging in the diagnosis and management of this condition.
Collapse
Affiliation(s)
- F F Syed
- Department of Internal Medicine, Groote Schuur Hospital and University of Cape Town, Observatory
| | | | | | | | | | | | | |
Collapse
|
18
|
Russell JB, Syed FF, Ntsekhe M, Mayosi BM, Moosa S, Tshifularo M, Smedema JP. Tuberculous effusive-constrictive pericarditis. Cardiovasc J Afr 2008; 19:200-201. [PMID: 18776964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
Infection with Mycobacterium tuberculosis and the human immunodeficiency virus has reached epidemic proportions in South Africa. Cardiac involvement occurs in approximately one per cent of patients suffering from active tuberculosis. This concerns predominantly pericardial involvement, resulting in chronic pericardial effusions, cardiac tamponade and constrictive pericarditis. Effusive-constrictive pericarditis is a clinical haemodynamic syndrome in which constriction by the visceral pericardium occurs in the presence of a tense effusion in a free pericardial space. We present a patient who was diagnosed with this condition, and highlight the value of contrast-enhanced magnetic resonance imaging in demonstrating the underlying structural and functional abnormalities.
Collapse
Affiliation(s)
- J B Russell
- Department of Internal Medicine, Groote Schuur Hospital and University of Cape Town, Observatory
| | | | | | | | | | | | | |
Collapse
|
19
|
Pugh PJ, Latib A, Ntsekhe M, Commerford PJ. An uncommon cause of aortic stenosis in an adult. Heart 2005; 91:1018. [PMID: 16020587 PMCID: PMC1769028 DOI: 10.1136/hrt.2004.059576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
20
|
Abstract
BACKGROUND There is controversy regarding the effectiveness of corticosteroids in tuberculous pericarditis, particularly in patients who are immunocompromised by HIV. AIM To determine the effectiveness of adjuvant corticosteroids in tuberculous pericarditis. DESIGN Systematic review of randomized controlled trials. METHODS We searched the Cochrane Infectious Diseases Group trials register (June 2002), the Cochrane Controlled Trials Register (Issue 2, 2002), MEDLINE (January 1966 to March 2003), EMBASE (1980 to May 2002), and the reference lists of existing reviews, for randomized and quasi-randomized controlled trials of adjuvant corticosteroids in the treatment of suspected tuberculous pericarditis. We also contacted organizations and individuals working in the field. Two reviewers independently assessed trial quality and extracted data. We used meta-analysis with a fixed effects model to calculate the summary statistics, provided there was no statistically significant heterogeneity, and expressed results as relative risk. RESULTS Four trials with a total of 469 participants met our criteria. Three (total n = 411) tested adjuvant steroids in participants with suspected tuberculous pericarditis in the pre-HIV era. Fewer participants died in the intervention group, but the potentially large reduction in mortality was not statistically significant (relative risk RR 0.65, 95%CI 0.36-1.16, n = 350; p = 0.14). One trial with 58 patients that enrolled HIV-positive individuals also showed a promising but non-significant trend on mortality (RR 0.50, 95%CI 0.19-1.28; p = 0.15). There was no significant beneficial effect of steroids on re-accumulation of pericardial effusion or progression to constrictive pericarditis. Patients with pericardial effusion were significantly more likely to be alive with no functional impairment at 2 years following treatment. However, the effect was not sustained in a sensitivity analysis that included patients who were lost to follow-up. DISCUSSION Steroids could have large beneficial effects on mortality and morbidity in tuberculous pericarditis, but published trials are too small to be conclusive. Large placebo-controlled trials are required, and should include sufficient numbers of HIV-positive and HIV-negative participants, and an adequate adjuvant steroid dose.
Collapse
Affiliation(s)
- M Ntsekhe
- Cardiac Clinic, Department of Medicine, Groote Schuur Hospital, Cape Town, South Africa
| | | | | | | | | |
Collapse
|
21
|
Abstract
BACKGROUND Tuberculous pericarditis - tuberculosis infection of the pericardial membrane (pericardium) covering the heart - is becoming more common. The infection can result in fluid around the heart or fibrosis of the pericardium, which can be fatal. OBJECTIVES In people with tuberculous pericarditis, to evaluate the effects on death, life-threatening conditions, and persistent disability of: (1) 6-month antituberculous drug regimens compared with regimens of 9 months or more; (2) corticosteroids; (3) pericardial drainage; and (4) pericardiectomy. SEARCH STRATEGY We searched the Cochrane Infectious Diseases Group trials register (June 2002), the Cochrane Controlled Trials Register (Issue 2, 2002), MEDLINE (1966 to June 2002), EMBASE (1980 to May 2002), and checked the reference lists of existing reviews. We also contacted organizations and individuals working in the field. SELECTION CRITERIA Randomized and quasi-randomized controlled trials of treatments for tuberculous pericarditis. DATA COLLECTION AND ANALYSIS Two reviewers independently assessed trial quality and extracted data. Meta-analysis using fixed effects models calculated summary statistics, provided there was no statistically significant heterogeneity, and expressed results as relative risk. Study authors were contacted for additional information. MAIN RESULTS Four trials met the inclusion criteria, with a total of 469 participants. Treatments tested were adjuvant steroids and surgical drainage. Two trials with a total of 383 participants tested adjuvant steroids in participants with suspected tuberculous pericarditis in the pre-HIV era. Fewer participants died in the intervention group, but numbers were small (relative risk [RR] 0.65; 95% confidence interval [CI] 0.36 to 1.16, n = 350). One small trial tested steroids in HIV positive participants with effusion showed a similar pattern (RR 0.50; 95% CI 0.19 to 1.28, n = 58). One trial examined open surgical drainage compared with conservative management, and showed surgery relieved cardiac tamponade. REVIEWER'S CONCLUSIONS Steroids could have important clinical benefits, but the trials published to date are too small to demonstrate an effect. This requires large placebo controlled trials. Subgroup analysis could explore whether effusion or fibrosis modify the effects. Therapeutic pericardiocentesis under local anaesthesia and pericardiectomy also require further evaluation.
Collapse
Affiliation(s)
- B M Mayosi
- The Cardiac Clinic, E25 Groote Schuur Hospital, Observatory 7925, Cape Town, South Africa.
| | | | | | | |
Collapse
|